| Nicole Maynard, AUD | |
|
1 Medical Center Dr, Dhmc Department Of Audiology Dept. 4f, Lebanon, NH 03756-1000 | |
| (603) 650-8123 | |
| (603) 650-0052 |
| Full Name | Nicole Maynard |
|---|---|
| Gender | Female |
| Speciality | Qualified Audiologist |
| Experience | 9 Years |
| Location | 1 Medical Center Dr, Lebanon, New Hampshire |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1578946364 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 231H00000X | Audiologist | A661 (New Hampshire) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Johnson Audiology Llc | 5092932871 | 3 |
News Archive
Early after trauma, changes in blood lactate over time, defined as lactate clearance, provide additional information predicting mortality in trauma patients according to a study from the December issue of Anesthesiology.
Women in the US will now have the same opportunity as million of European women already have; to undergo mammography with significantly lower radiation dose. This is the result of FDA's clearance of the Swedish IT and medical technology company Sectra's digital mammography system, Sectra MicroDose Mammography.
Protalix Biotherapeutics, Inc. today announced the completion of its New Drug Application (NDA) submission with the U.S. Food and Drug Administration (FDA) for taliglucerase alfa, a plant-cell expressed form of glucocerebrosidase (GCD) for the potential treatment of Gaucher's disease.
Amylin Pharmaceuticals, Inc. and Eli Lilly and Company today announced that a supplemental New Drug Application (sNDA) has been submitted to the U.S. Food and Drug Administration (FDA) for the expanded use of BYETTA® (exenatide) injection as an add-on therapy to basal insulin, with or without metformin and/or a thiazolidinedione (TZD) in conjunction with diet and exercise for adults with type 2 diabetes who are not achieving adequate glycemic control.
› Verified 8 days ago
| Provider Name | Mary Hitchcock Memorial Hospital |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1023092053 PECOS PAC ID: 4486561164 Enrollment ID: O20031126000258 |
News Archive
Early after trauma, changes in blood lactate over time, defined as lactate clearance, provide additional information predicting mortality in trauma patients according to a study from the December issue of Anesthesiology.
Women in the US will now have the same opportunity as million of European women already have; to undergo mammography with significantly lower radiation dose. This is the result of FDA's clearance of the Swedish IT and medical technology company Sectra's digital mammography system, Sectra MicroDose Mammography.
Protalix Biotherapeutics, Inc. today announced the completion of its New Drug Application (NDA) submission with the U.S. Food and Drug Administration (FDA) for taliglucerase alfa, a plant-cell expressed form of glucocerebrosidase (GCD) for the potential treatment of Gaucher's disease.
Amylin Pharmaceuticals, Inc. and Eli Lilly and Company today announced that a supplemental New Drug Application (sNDA) has been submitted to the U.S. Food and Drug Administration (FDA) for the expanded use of BYETTA® (exenatide) injection as an add-on therapy to basal insulin, with or without metformin and/or a thiazolidinedione (TZD) in conjunction with diet and exercise for adults with type 2 diabetes who are not achieving adequate glycemic control.
› Verified 8 days ago
| Provider Name | Dartmouth-hitchcock Clinic |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1548210198 PECOS PAC ID: 4183537509 Enrollment ID: O20040809000442 |
News Archive
Early after trauma, changes in blood lactate over time, defined as lactate clearance, provide additional information predicting mortality in trauma patients according to a study from the December issue of Anesthesiology.
Women in the US will now have the same opportunity as million of European women already have; to undergo mammography with significantly lower radiation dose. This is the result of FDA's clearance of the Swedish IT and medical technology company Sectra's digital mammography system, Sectra MicroDose Mammography.
Protalix Biotherapeutics, Inc. today announced the completion of its New Drug Application (NDA) submission with the U.S. Food and Drug Administration (FDA) for taliglucerase alfa, a plant-cell expressed form of glucocerebrosidase (GCD) for the potential treatment of Gaucher's disease.
Amylin Pharmaceuticals, Inc. and Eli Lilly and Company today announced that a supplemental New Drug Application (sNDA) has been submitted to the U.S. Food and Drug Administration (FDA) for the expanded use of BYETTA® (exenatide) injection as an add-on therapy to basal insulin, with or without metformin and/or a thiazolidinedione (TZD) in conjunction with diet and exercise for adults with type 2 diabetes who are not achieving adequate glycemic control.
› Verified 8 days ago
| Provider Name | Johnson Audiology Llc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1881017390 PECOS PAC ID: 5092932871 Enrollment ID: O20140819001884 |
News Archive
Early after trauma, changes in blood lactate over time, defined as lactate clearance, provide additional information predicting mortality in trauma patients according to a study from the December issue of Anesthesiology.
Women in the US will now have the same opportunity as million of European women already have; to undergo mammography with significantly lower radiation dose. This is the result of FDA's clearance of the Swedish IT and medical technology company Sectra's digital mammography system, Sectra MicroDose Mammography.
Protalix Biotherapeutics, Inc. today announced the completion of its New Drug Application (NDA) submission with the U.S. Food and Drug Administration (FDA) for taliglucerase alfa, a plant-cell expressed form of glucocerebrosidase (GCD) for the potential treatment of Gaucher's disease.
Amylin Pharmaceuticals, Inc. and Eli Lilly and Company today announced that a supplemental New Drug Application (sNDA) has been submitted to the U.S. Food and Drug Administration (FDA) for the expanded use of BYETTA® (exenatide) injection as an add-on therapy to basal insulin, with or without metformin and/or a thiazolidinedione (TZD) in conjunction with diet and exercise for adults with type 2 diabetes who are not achieving adequate glycemic control.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Nicole Maynard, AUD 1 Medical Center Dr, Dhmc Department Of Audiology Dept. 4f, Lebanon, NH 03756-1000 Ph: (603) 650-8123 | Nicole Maynard, AUD 1 Medical Center Dr, Dhmc Department Of Audiology Dept. 4f, Lebanon, NH 03756-1000 Ph: (603) 650-8123 |
News Archive
Early after trauma, changes in blood lactate over time, defined as lactate clearance, provide additional information predicting mortality in trauma patients according to a study from the December issue of Anesthesiology.
Women in the US will now have the same opportunity as million of European women already have; to undergo mammography with significantly lower radiation dose. This is the result of FDA's clearance of the Swedish IT and medical technology company Sectra's digital mammography system, Sectra MicroDose Mammography.
Protalix Biotherapeutics, Inc. today announced the completion of its New Drug Application (NDA) submission with the U.S. Food and Drug Administration (FDA) for taliglucerase alfa, a plant-cell expressed form of glucocerebrosidase (GCD) for the potential treatment of Gaucher's disease.
Amylin Pharmaceuticals, Inc. and Eli Lilly and Company today announced that a supplemental New Drug Application (sNDA) has been submitted to the U.S. Food and Drug Administration (FDA) for the expanded use of BYETTA® (exenatide) injection as an add-on therapy to basal insulin, with or without metformin and/or a thiazolidinedione (TZD) in conjunction with diet and exercise for adults with type 2 diabetes who are not achieving adequate glycemic control.
› Verified 8 days ago
Dr. Kathryn E Hardacre, AU.D. Audiologist Medicare: Medicare Enrolled Practice Location: 1 Medical Center Dr # 4f, Lebanon, NH 03756 Phone: 603-650-8123 | |
Mrs. Erin V Pospychala, M.S. Audiologist Medicare: Accepting Medicare Assignments Practice Location: 1 Medical Center Dr, Dhmc Audiology, Lebanon, NH 03756 Phone: 603-650-6151 | |
Catherine Clara Rieke, AU.D. Audiologist Medicare: Medicare Enrolled Practice Location: 1 Medical Center Dr, Lebanon, NH 03756 Phone: 603-650-8123 | |
Dr. Ashley Nicole Perez, AU.D. Audiologist Medicare: Accepting Medicare Assignments Practice Location: 1 Medical Center Dr, Dhmc Department Of Surgery, Lebanon, NH 03756 Phone: 603-650-8123 Fax: 603-650-0052 | |
Maria Stella Mchugh, M.S. Audiologist Medicare: Accepting Medicare Assignments Practice Location: 1 Medical Center Dr, Lebanon, NH 03756 Phone: 603-650-8123 | |
Ms. Samantha Glover, AUD Audiologist Medicare: Accepting Medicare Assignments Practice Location: 1 Medical Center Dr, Dhmc - Department Of Surgery, Lebanon, NH 03756 Phone: 603-650-2068 | |
Danielle N Shine, AUD Audiologist Medicare: Accepting Medicare Assignments Practice Location: One Medical Center Dr, Lebanon, NH 03756 Phone: 603-650-9761 |